Vanguard Personalized Indexing Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,056	Closed	-$45.8K	–	1931
2024 Q4	$45.8K	Buy	15,056 +712	+5%	+$3.1K	﹤0.01%	1705
2024 Q3	$74.4K	Buy	14,344 +1,685	+13%	+$8.37K	﹤0.01%	1648
2024 Q2	$32.5K	Buy	+12,659	New	+$43.2K	﹤0.01%	1617

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Personalized Indexing Management's RVNC Position: Q1 2025 in Review

Vanguard Personalized Indexing Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 15,056 shares — an estimated $45.8K sold.

Vanguard Personalized Indexing Management first reported a position in RVNC in Q2 2024 and held it in 3 quarters. The position peaked at $74.4K in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Vanguard Personalized Indexing Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Vanguard Personalized Indexing Management sold 15,056 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $45.8K.
Vanguard Personalized Indexing Management first reported a position in Revance Therapeutics, Inc. in Q2 2024 and held it in 3 quarters.
Vanguard Personalized Indexing Management's Revance Therapeutics, Inc. position peaked at $74.4K in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2025, filed 14 May 2025.